Roche says data in hepatitis treatment encouraging

ZURICH Thu Apr 19, 2012 11:06am IST

Related Topics

Stocks

   
Priyanka Gandhi Vadra, daughter of Congress party chief Sonia Gandhi, adjusts her flower garlands as she campaigns for her mother during an election meeting at Rae Bareli in Uttar Pradesh April 22, 2014. REUTERS/Pawan Kumar

Election 2014

More than 814 million people — a number larger than the population of Europe — are eligible to vote in the world’s biggest democratic exercise.  Full Coverage 

ZURICH (Reuters) - Swiss drugmaker Roche said on Thursday initial data on a protease inhibitor, danoprevir, is encouraging against Hepatitis C.

"The high sustained viral response rates and encouraging safety data show danoprevir is potent and well-tolerated," Roche development head Hal Barron said in a statement.

"Roche's HCV portfolio includes multiple investigational drugs with different modes of action, allowing us to develop tailored treatments that aim to address the future needs of patients with chronic hepatitis C," Barron said.

(Reporting By Katharina Bart)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

ALLERGY WORRIES

Reuters Showcase

A Little Help

A Little Help

Researchers "buzz" the brain to speed up learning.  Video 

Disease Outbreak

Disease Outbreak

WHO says West African Ebola outbreak to last 2-4 months.  Full Article 

Healthy Food

Healthy Food

For teen girls, fruits and veggies linked to lower risk of breast condition.  Full Article 

Milk Effect

Milk Effect

Drinking milk may slow women's knee arthritis.  Full Article 

Rising Obesity

Rising Obesity

U.S. childhood obesity rates have increased since 1999: study.  Full Article 

Quality Check

Quality Check

Just because it's sweet and sticky doesn't mean it's 'honey': FDA.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.   Full Coverage